|
KMID : 0939920230550041363
|
|
대한암학회지
2023 Volume.55 No. 4 p.1363 ~ p.1368
|
|
|
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
|
|
Isaratat Phung-on
Xiao Zhou
Hailing Liu
Peng Wang
Fan Xia
Liqing Kang
Lei Yu
Depei Wu
Zhengming Jin
Changju Qu
|
|
|
Abstract
|
|
|
|
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin’s lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neurotoxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton’s tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.
|
|
|
KEYWORD
|
|
|
Chimeric antigen receptor T-cell therapy, Primary central nervous system lymphoma, Diffuse large B-cell lymphoma, CD19/CD22, Decitabine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|